跳至主要内容
临床试验/jRCT1051180028
jRCT1051180028已完成不适用

Induction Chemotherapy and Adjuvant Thoracic Radiation in Resectable Stage N2-3A/3B Non-small Cell Lung Cancer (ICAT in N2-3A/3B NSCLC)

未提供0 个研究点目标入组 25 人开始时间: 2019年3月7日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
25
主要终点
-

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Single Arm Study
干预模型
Single Assignment
主要目的
Treatment Purpose
盲法
Open(masking Not Used)

入排标准

年龄范围
20age old over 至 75age old not(—)
性别
All

入选标准

  • c-stage 3A/3B with pathologically diagnosed N2 without chest wall invasion
  • 2.Resectable following induction chemotherapy
  • 3.Normal pulmonary function within 56days before IC
  • 4.No previous chemotherapy or thoracic radiation
  • 5.age 20-75 years at IC
  • 6.ECOG Performance Status0-1
  • 7.Normal bone marrow, liver, and renal function below within 28days before IC
  • 8.Written informed consent was obtained

排除标准

  • 1.Unresectable extra-nodal mediastinal lymph node in CT
  • 2.Contraindication for CBDCA or nab-PTX
  • 3.Past history of severe drug allergy
  • 4.Pulmonary dysfunction
  • 5.Myocardial infarction within 180 days before IC
  • 6.Interstitial pneumonia or pulmonary fibrosis detected in CT 56days before IC
  • 7.Medication with PSL more than 10mg/day 90days before IC
  • 8.Clinically relevant heart disease
  • 9.Clinically relevant psychological disorder
  • 10.Uncontrollable DM
  • 11.Clinically relevant infection disease
  • 12.Other clinically relevant comorbidity
  • 13.Active double cancer
  • 14.Pregnant, lactating, possibly pregnant
  • 15.Inappropriate by investigator

结局指标

主要结局

-

Treatment completion

次要结局

未报告次要终点

研究者

发起方
未提供

相似试验